Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (51-60 of 251) with videos related to

Pageof 26
Sort By:
Leukemia & Lymphoma|May 16, 2012
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline inductionThomas Prébet, Estelle Jean, Aurélie Autret, et al.
Haematologica|November 21, 2007
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial resultsArnaud Pigneux, Virginie Perreau, Eric Jourdan, et al.
HLA|November 10, 2023
Comparison of HLA antibody identification methods for the selection of platelet products for HLA-mediated platelet refractory patientsPascal Pedini, Lucas Hubert, Jean-Baptiste Baudey, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 23, 2019
Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to AnthracyclinesClemence Marcault, Geoffroy Venton, Lauris Gastaud, et al.
Cancer|February 28, 2007
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemiaAnne Etienne, Benjamin Esterni, Aude Charbonnier, et al.
Leukemia & Lymphoma|December 3, 2016
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemiaNorbert Vey, Thomas Prebet, Claire Thalamas, et al.
American Journal of Hematology|November 18, 2017
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasmsGeoffroy Venton, Frédéric Courtier, Aude Charbonnier, et al.
Cancer|October 30, 2007
Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trialsEmmanuelle Tavernier, Quoc-Hung Le, Stéphane de Botton, et al.
Bone Marrow Transplantation|April 29, 2018
Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortalityColombe Saillard, Michael Darmon, Magali Bisbal, et al.
Bone Marrow Transplantation|August 8, 2018
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-CalmettesLing Wang, Raynier Devillier, Ming Wan, et al.
Pageof 26

Showing results (51-60 of 251) with videos related to

Sort By:
Pageof 26
Leukemia & Lymphoma|May 16, 2012
Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline inductionThomas Prébet, Estelle Jean, Aurélie Autret, et al.
Haematologica|November 21, 2007
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial resultsArnaud Pigneux, Virginie Perreau, Eric Jourdan, et al.
HLA|November 10, 2023
Comparison of HLA antibody identification methods for the selection of platelet products for HLA-mediated platelet refractory patientsPascal Pedini, Lucas Hubert, Jean-Baptiste Baudey, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 23, 2019
Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to AnthracyclinesClemence Marcault, Geoffroy Venton, Lauris Gastaud, et al.
Cancer|February 28, 2007
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemiaAnne Etienne, Benjamin Esterni, Aude Charbonnier, et al.
Leukemia & Lymphoma|December 3, 2016
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemiaNorbert Vey, Thomas Prebet, Claire Thalamas, et al.
American Journal of Hematology|November 18, 2017
Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasmsGeoffroy Venton, Frédéric Courtier, Aude Charbonnier, et al.
Cancer|October 30, 2007
Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trialsEmmanuelle Tavernier, Quoc-Hung Le, Stéphane de Botton, et al.
Bone Marrow Transplantation|April 29, 2018
Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortalityColombe Saillard, Michael Darmon, Magali Bisbal, et al.
Bone Marrow Transplantation|August 8, 2018
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-CalmettesLing Wang, Raynier Devillier, Ming Wan, et al.
Pageof 26